On this basis, synthetic or recombinant Abeta oligomers have been administered both in in vitro and in vivo model systems to mimic the AD pathology and study the possibility to inhibit its progression by using drugs or natural compounds [22, 23, 30–32]. This evidence concerns the gene APP and Alzheimer disease.